Jaguar Health regains Nasdaq bid price compliance
Jaguar Health, Inc. has regained compliance with Nasdaq’s minimum bid price listing rule.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jaguar Health, Inc. has regained compliance with Nasdaq’s minimum bid price listing rule. Nasdaq formally notified the company on May 26, 2026, and its shares continue to trade on Nasdaq, although a Nasdaq Hearings Panel will retain jurisdiction over the listing until September 1, 2026.
The company is now subject to a one-year Mandatory Panel Monitor period through May 26, 2027. If during this time the closing bid falls below $1.00 per share for 30 consecutive business days, Nasdaq would issue a delist determination without granting the usual 180‑day grace period, though Jaguar could request a new hearing.
In the accompanying press release, Jaguar highlighted that net revenue in Q1 2026 increased 816% versus Q1 2025 and 527% versus Q4 2025, driven by a U.S. out‑license agreement for Mytesi and Canalevia‑CA1 with Future Pak. The company also reiterated its focus on a pivotal‑stage development program for crofelemer in rare intestinal failure indications, targeting a new drug application around mid‑2027 and seeking a development and commercialization partner.
Positive
- Nasdaq bid price compliance regained: Jaguar received formal notice on May 26, 2026 that it now meets Nasdaq Listing Rule 5550(a)(2), preserving its Nasdaq trading status.
- Very strong recent revenue growth: Q1 2026 net revenue increased 816% versus Q1 2025 and 527% versus Q4 2025, driven by a U.S. out‑license agreement for Mytesi and Canalevia‑CA1 with Future Pak.
Negative
- Heightened delisting risk during monitoring: For one year after May 26, 2026, any new 30‑day period with a closing bid below $1.00 would prompt a delist determination without the usual 180‑day grace period, requiring Jaguar to seek another hearing to avoid removal.
Insights
Jaguar regains Nasdaq compliance but remains under close monitoring.
Jaguar Health has restored compliance with Nasdaq’s Bid Price Rule, keeping its shares listed. However, the Nasdaq Hearings Panel will oversee the listing until September 1, 2026, and a Mandatory Panel Monitor applies for one year from the compliance date.
During this monitor period, a fresh stretch of sub‑$1.00 closing bids for 30 straight business days would trigger an immediate delist determination, without the standard 180‑day cure window. Jaguar could request another hearing, but continued compliance depends on sustained market pricing.
The press release also cites very large net revenue gains in Q1 2026—up 816% year over year and 527% sequentially—linked to a U.S. out‑license deal with Future Pak. Future filings for periods after Q1 2026 will clarify whether this revenue step‑change is durable while Jaguar advances its crofelemer program toward a targeted NDA in mid‑2027.
8-K Event Classification
Key Figures
Key Terms
Nasdaq Listing Rule 5550(a)(2) regulatory
Bid Price Rule regulatory
Mandatory Panel Monitor regulatory
Nasdaq Hearings Panel regulatory
out-license agreement financial
new drug application regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Jaguar Health (JAGX) announce about its Nasdaq listing status?
What is the Mandatory Panel Monitor affecting Jaguar Health (JAGX)?
How did Jaguar Health’s Q1 2026 net revenue perform versus prior periods?
What happens if Jaguar Health’s stock falls below $1.00 again during monitoring?
How long will the Nasdaq Hearings Panel retain jurisdiction over Jaguar Health?
What are Jaguar Health’s development plans for crofelemer mentioned in the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01. | Regulation FD Disclosure. |
On May 27, 2026, Jaguar Health, Inc. (the “Company”) issued a press release announcing the Decision Letter (as defined below) from the Nasdaq Hearings Panel, a copy of which is furnished as Exhibit 99.1.
The information in Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| Item 8.01. | Other Events. |
As previously disclosed, on April 24, 2026, the Company received formal notice that the Nasdaq Hearings Panel (“Panel”) had granted the Company’s request for continued listing on The Nasdaq Stock Market LLC (“Nasdaq”), subject to the condition that the Company demonstrate compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) by May 15, 2026. On May 6, 2026, the Company received a superseding decision from the Panel granting the Company’s request for an extension to demonstrate compliance with the Bid Price Rule, from May 15, 2026, to May 18, 2026.
On May 26, 2026, the Company was formally notified by Nasdaq that the Company had regained compliance with the Bid Price Rule (the “Compliance Determination”) but that the Panel would maintain jurisdiction over the Company and its listing until September 1, 2026, the outside date of the Panel’s discretion in this matter.
The Compliance Determination further stated that, in accordance with Listing Rule 5815(d)(4)(B), the Company is subject to a Mandatory Panel Monitor for a period of one year from the date of the Compliance Determination, or May 26, 2027. If within the one-year monitoring period Nasdaq determines that the Company has failed to evidence a closing bid price of at least $1.00 per share for 30 consecutive business days, the Company will not be afforded a 180-day grace period otherwise automatically available under Listing Rule 5810(c)(3). Rather, Nasdaq would issue a delist determination, at which time the Company may request a new hearing before the Panel. The Company’s request for a hearing would stay any further action by Nasdaq at least pending the hearing and the expiration of any extension period that may be granted by the Panel following such hearing.
This Current Report on Form 8-K contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. While the Company believes its plans, intentions and expectations reflected in those forward-looking statements are reasonable, these plans, intentions or expectations may not be achieved. The Company’s actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements. For information about the factors that could cause such differences, please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, including the information discussed under the captions “Item 1 Business,” “Item 1A. Risk Factors” and “Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as the Company’s various other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company assumes no obligation to update any forward-looking statement.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Description | |
| 99.1 | Press Release dated May 27, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| JAGUAR HEALTH, INC. | ||||||
| Date: May 27, 2026 | By: | /s/ Lisa A. Conte | ||||
| Lisa A. Conte | ||||||
| Chief Executive Officer & President | ||||||
Exhibit 99.1
Jaguar Health Compliant with Nasdaq Bid Price Rule
JAGX’s securities continue to be listed and traded on Nasdaq
SAN FRANCISCO, CA / May 27, 2026 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that Jaguar has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).
“We are very happy that Jaguar has regained compliance with the Nasdaq listing criteria. We consider our Nasdaq listing an asset of the Company,” said Lisa Conte, Jaguar’s president and CEO. “As we were pleased to report on May 20, 2026, Jaguar’s net revenue increased 816% in Q1 2026 versus Q1 2025, and increased 527% in Q1 2026 over the previous quarter, Q4 2025, buoyed by the US out-license agreement we executed with Future Pak for Mytesi and Canalevia-CA1 this past January. We continue to sharply focus on our pivotal-stage development program for our novel proprietary powder-for-oral-solution formulation of crofelemer for rare intestinal failure indications, targeting an NDA in mid-2027, and on identifying a development and commercialization partner for this program.”
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX